Evidence map›Paper›PMID 37402477›Full record

ReviewHuman vaccines & immunotherapeutics2023

Review of the unmet medical need for vaccination in adults with immunocompromising conditions: An Indian perspective.

Ashok Vaid, Neha Rastogi, T Mark Doherty, Peter San Martin, Yashpal Chugh

Open access · goldAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Ashok VaidMedical Oncology and Hematology, Medanta Cancer Institute, Gurugram, India.
Neha RastogiPediatric Hematology, Oncology and BMT, Medanta Cancer Institute, Gurugram, India.
T Mark DohertyGSK, Brondby, Denmark.
Peter San MartinGSK, Wavre, Belgium.
Yashpal ChughGSK, Mumbai, India.ORCID 0000-0002-5591-6169
Cancer Institute (WIA) · INGlaxoSmithKline (Belgium) · BEGlaxoSmithKline (India) · INOptical Fiber Solutions (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunocompromised (IC) populations are at increased risk of vaccine-preventable diseases (VPDs). In India, the concern of VPDs in IC populations is particularly acute due to the prevalence of crowded living situations, poor sanitation and variable access to healthcare services. We present a narrative review of IC-related disease and economic burden, risk of VPDs and vaccination guidelines, based on global and India-specific literature (2000-2022). IC conditions considered were cancer, diabetes mellitus, chronic kidney disease, respiratory disorders, disorders treated with immunosuppressive therapy, and human immune deficiency virus (HIV). The burden of IC populations in India is comparable to the global population, except for cancer and HIV, which have lower prevalence compared with the global average. Regional and socioeconomic inequalities exist in IC prevalence; VPDs add to the burden of IC conditions, especially in lower income strata. Adult vaccination programs could improve health and reduce the economic impact of VPDs in IC populations.

Indexed as

VaccinationAdultHumansIndiaDisease burdeneconomic burdenimmunocompromised populationsIndiavaccination guidelines for immunocompromised peoplevaccine-preventable diseases

Identifiers

PMID37402477
PMCPMC10321191
OpenAlexW4383100609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.